检索结果-南通市图书馆

Detection of an anti-angina therapeutic module in the effective population treated by a multi-target drug Danhong injection:a randomized trial

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2021年第10期6卷 3009-3018页

作者： Jun liu Dan-Dan Li Wei Dong Yu-Qi liu Yang Wu Da-Xuan Tang Fu-Chun Zhang Meng Qiu Qi Hua Jing-Yu He Jun Li Bai Du Ting-Hai Du Lin-Lin Niu Xue-Jun jiang bo Cui jiang-Bin Chen Yang-Gan wang Hai-Rong wang qin Yu Jing He Yi-Lin Mao Xiao-Fang Bin yue Deng Yu-Dan Tian qing-Hua Han Da-Jin liu Li-qin Duan Ming-Jun Zhao Cui-Ying Zhang Hai-Ying Dai Ze-Hua Li Ying Xiao You-Zhi Hu Xiao-Yu Huang Kun Xing Xin jiang Chao-Feng liu Jing An Feng-Chun Li Tao Tao Jin-Fa jiang Ying Yang Yao-Rong Dong Lei Zhang Guang Fu Ying Li Shu-Wei Huang Li-ping Dou Lan-Jun Sun Ying-Qiang Zhao Jie Li Yun Xia Jun liu Fan liu Wen-Jin He Ying Li Jian-Cong Tan Yang Lin Ya-Bin Zhou Jian-Fei Yang Guo-qing Ma Hui-Jun Chen He-ping liu Zong-Wu liu Jian-Xiong liu Xiao-Jia Luo Xiao-hong Bin Ya-Nan Yu Hai-Xia Dang Bing Li Fei Teng wang-Min Qiao Xiao-Long Zhu Bing-Wei Chen Qi-Guang Chen Chun-Ti Shen Yong-Yan wang Yun-Dai Chen Zhong wang Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical SciencesBeijingChina Department of Cardiology Chinese PLA General HospitalBeijingChina Department of Cardiology Dongfang Hospital Affiliated to Beijing University of Chinese MedicineBeijingChina Department of Geratology Peking University Third HospitalBeijingChina Department of Cardiology Xuan Wu HospitalCapital Medical UniversityBeijingChina Department of Cardiology Guang'anmen HospitalChina Academy of Chinese Medical SciencesBeijingChina Department of Cardiology First Affiliated Hospital of Henan University of Chinese MedicineZhengzhouHenanChina Department of Cardiology Wuhan University Renmin HospitalWuhanHubeiChina Department of Cardiology Wuhan University Zhongnan HospitalWuhanHubeiChina Affiliated Zhongshan Hospital of Dalian University DalianLiaoningChina Department of Cardiology Second Affiliated Hospital to Hunan University of Chinese MedicineChangshaHunanChina Department of Cardiology First Affiliated Hospital to Changchun University of Chinese MedicineChangchunJilinChina Department of Cardiology First Affiliated Hospital to Shanxi Medical UniversityTaiyuanShanxiChina Department of Cardiology Affiliated Hospital of Shanxi University of Chinese MedicineXianyangShanxiChina Department of Cardiology Changsha Central HospitalChangshaHunanChina Department of Cardiology Hubei Provincial Hospital of Traditional Chinese MedicineWuhanHubeiChina Department of Cardiology Shanxi Provincial People's HospitalXi'anShanxiChina Department of Cardiology Shanxi Province Hospital of Traditional Chinese MedicineXi'anShanxiChina Department of Cardiology Xi'an City Hospital of Traditional Chinese MedicineXi'anShanxiChina Department of Cardiology Shanghai Tongji HospitalShanghaiChina Department of Cardiology Shanghai Municipal Hospital of Traditional Chinese MedicineShanghaiChina Department of Cardiology The First Hospital of ChangshaChangshaHunanChina Department of Cardiology Xinhua Hospi

It's a challenge for detecting the therapeutic targets of a polypharmacological drug from variations in the responsed networks in thedfferentiated populations with complex diseases,as stable coronary heart ***,in an adaptive,31-center,randomized,double-blind trial invoving 920 patients with moderate symptomatic stable angina treated by 14-day Danhong injection(DHI),a kind of polyphamacological drug with high quality control,or placebo(0.9%saline),with 76-day following-up,we firstly confrmed that DHl couldincrease the proportion of patients with clinically significant changes on angina-frequency assessed by Seattle Angina Questionnaire(ASAQ-AF220)(12.78%at Day 30,95%confidence interval[C]5.86-19.71%,P=0.0003,13.82%at Day 6C0,95%CI 6.82-20.82%,P=0.0001and 8.95%at Day 90,95%CI 2.06-15.85%,P=0.01).We also found that there were no significant differences in new-onset major vascularevents(P=0.8502)and serious adverse events(P=0.9105)between DHl and *** performing the RNA sequencing in 62 selectedpatients,we developed a systemic modular approach tp identfy differentilly expressed modules(DEMs)of DHI with the Z_(summay)valueless than 0 compared with the control group,calculated by weighted gene co-expression network analysis(WGCNA),and sketched out thebasic framework on a modular map with 25 functional modules targeted by ***,the effective therapeutic module(ETM),defined as the highest corelation value with the phenotype alteration(SAQ-AF,the change in SAQ-AF at Day 30 from baseline)calculatedby WGCNA,was identifed in the population with the best effect(ASAQ-AF240),which is related to anticoagulation and regulation ofcholesterol *** assessed the modular flexbility of this ETM using the global topological D value based on Euclidean distance,which is corelated with phenotype alteration(r^(2):0.8204,P=0.019)by linear *** study identified the ant-angina therapeuticmodule in the effective population treated by the multi-target

关键词： angina injection sketch

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

煤岩体冲击地压储能机理发生条件的研究

采矿与安全工程学报 2008年第4期25卷 472-475页

作者：武玉梁秦跃平刘宏波王科四川省安全科学技术研究院矿山安全研究所四川成都610012 中国矿业大学煤炭资源与安全开采国家重点实验室北京100083

为了进一步定量分析冲击地压的发生时间、地点、强度等特征,结合对岩体性状组织损伤弱化的分析,提出了煤岩体发生冲击效应的区域能量方程,从能量的观点对煤岩的力学性质进行了多方面的探究,建立了煤岩损伤本构方程,论述了冲击地压的形... 详细信息

为了进一步定量分析冲击地压的发生时间、地点、强度等特征,结合对岩体性状组织损伤弱化的分析,提出了煤岩体发生冲击效应的区域能量方程,从能量的观点对煤岩的力学性质进行了多方面的探究,建立了煤岩损伤本构方程,论述了冲击地压的形成机理.结果表明,冲击地压过程实际上是加速损伤过程,冲击地压的发生有两个必要条件:一是岩石为第Ⅱ类岩石,二是巷道壁面产生足够大的变形,并提出预防冲击地压的措施.

关键词：应力场弹性能冲击地压

bone marrow-derived CXCR4-overexpressing MSCs display increased homing to intestine and ameliorate colitis-associated tumorigenesis in mice

在线全文

学校读者我要写书评

暂无评论

Gastroenterology Report 2019年第2期7卷 127-138,I0002页

作者： Xiao-Bin Zheng Xiao-Wen He Long-Juan Zhang Hua-bo qin Xu-Tao Lin Xuan-Hui liu Chi Zhou Hua-Shan liu Tuo Hu Hai-Chun Cheng Xiao-Sheng He Xian-Rui Wu Yu-Feng Chen Jia ke Xiao-Jian Wu ping Lan Department of Colorectal Surgery The Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhouGuangdong 510655P.R.China Guangdong Provincial key Laboratory of Colorectal and Pelvic Floor Diseases The Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhouGuangdong 510655P.R.China Laboratory of Surgery The First Affiliated Hospital of Sun Yat-sen UniversityGuangzhouGuangdong 510080P.R.China Department of Gastrointestinal Endoscopy The Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhouGuangdong 510655P.R.China Department of Gastrointestinal Surgery Shenzhen Baoan Shajing People’s HospitalGuangzhou Medical UniversityShenzhenGuangdong 518104P.R.China

Background and Objective:Increasing interest has developed in the therapeutic potential of bone marrow-derived mesenchymal stem cells(MSCs)for the treatment of inflammatory bowel disease(IBD)and IBD-induced ***,whether MSCs have the ability to suppress or promote tumor development remains *** stromal cell-derived factor 1(SDF-1)/C-X-C chemokine receptor type 4(CXCR4)axis is well known to play a critical role in the homing of *** this study,we aimed to evaluate the role of CXCR4-overexpressing MSCs on the tumorigenesis of ***:MSCs were transduced with lentiviral vector carrying either CXCR4 or green fluorescent protein(GFP).Chemotaxis and invasion assays were used to detect CXCR4 expression.A mouse model of colitis-associated tumorigenesis was established using azoxymethane and dextran sulfate sodium(DSS).The mice were divided into three groups and then injected with phosphate buffer saline(PBS),MSC-GFP or ***:Compared with the mice injected with MSC-GFP,the mice injected with MSC-CXCR4 showed relieved weight loss,longer colons,lower tumor numbers and decreased tumor load;expression of pro-inflammatory cytokines decreased,and signal transducer and activator of transcription 3(STAT3)phosphorylation level in colon tissue was ***:CXCR4-overexpressing MSCs exhibited effective anti-tumor function,which may be associated with enhanced homing to inflamed intestinal tissues.

关键词： Inflammatory bowel disease tumorigenesis mesenchymal stem cells CXCR4 mice

Determination of the number ofψ(3686)events taken at BESⅢ

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Physics C 2024年第9期48卷 8-20页

作者： M.Ablikim M.N.Achasov P.Adlarson O.Afedulidis X.C.Ai R.Aliberti A.Amoroso Q.An Y.Bai O.Bakina I.Balossino Y.Ban H.-R.Bao V.Batozskaya K.Begzsuren N.Berger M.Berlowski M.Bertani D.Bettoni F.Bianchi E.Bianco A.bortone I.boyko R.A.Briere A.Brueggemann H.Cai X.Cai A.Calcaterra G.F.Cao N.Cao S.A.Cetin J.F.Chang G.R.Che G.Chelkov C.Chen C.H.Chen Chao Chen G.Chen H.S.Chen H.Y.Chen M.L.Chen S.J.Chen S.L.Chen S.M.Chen T.Chen X.R.Chen X.T.Chen Y.B.Chen Y.Q.Chen Z.J.Chen Z.Y.Chen S.K.Choi G.Cibinetto F.Cossio J.J.Cui H.L.Dai J.P.Dai A.Dbeyssi R.E.de boer D.Dedovich C.Q.Deng Z.Y.Deng A.Denig I.Denysenko M.Destefanis F.De Mori B.Ding X.X.Ding Y.Ding Y.Ding J.Dong L.Y.Dong M.Y.Dong X.Dong M.C.Du S.X.Du Y.Y.Duan Z.H.Duan P.Egorov Y.H.Fan J.Fang J.Fang S.S.Fang W.X.Fang Y.Fang Y.Q.Fang R.Farinelli L.Fava F.Feldbauer G.Felici C.Q.Feng J.H.Feng Y.T.Feng M.Fritsch C.D.Fu J.L.Fu Y.W.Fu H.Gao X.B.Gao Y.N.Gao Yang Gao S.Garbolino I.Garzia L.Ge P.T.Ge Z.W.Ge C.Geng E.M.Gersabeck A.Gilman K.Goetzen L.Gong W.X.Gong W.Gradl S.Gramigna M.Greco M.H.Gu Y.T.Gu C.Y.Guan Z.L.Guan A.Q.Guo L.B.Guo M.J.Guo R.P.Guo Y.P.Guo A.Guskov J.Gutierrez K.L.Han T.T.Han F.Hanisch X.Q.Hao F.A.Harris K.K.He K.L.He F.H.Heinsius C.H.Heinz Y.K.Heng C.Herold T.Holtmann P.C.hong G.Y.Hou X.T.Hou Y.R.Hou Z.L.Hou B.Y.Hu H.M.Hu J.F.Hu S.L.Hu T.Hu Y.Hu G.S.Huang K.X.Huang L.Q.Huang X.T.Huang Y.P.Huang T.Hussain F.Hölzken N.Hüsken N.in der Wiesche J.Jackson S.Janchiv J.H.Jeong Q.Ji Q.P.Ji W.Ji X.B.Ji X.L.Ji Y.Y.Ji X.Q.Jia Z.K.Jia D.jiang H.B.jiang P.C.jiang S.S.jiang T.J.jiang X.S.jiang Y.jiang J.B.Jiao J.K.Jiao Z.Jiao S.Jin Y.Jin M.Q.Jing X.M.Jing T.Johansson S.Kabana N.Kalantar-Nayestanaki X.L.Kang X.S.Kang M.Kavatsyuk B.C.ke V.Khachatryan A.Khoukaz R.Kiuchi O.B.Kolcu B.Kopf M.Kuessner X.Kui N.Kumar A.Kupsc W.Kühn J.J.Lane P.Larin L.Lavezzi T.T.Lei Z.H.Lei M.Lellmann T.Lenz C.Li C.Li C.H.Li Cheng Li D.M.Li F.Li G.Li H.B.Li H.J.Li H.N.Li Hui Li J.R.Li J.S.Li ke Li L.J.Li L.K.Li Lei Li M.H.Li P.R.Li Q.M.Li Q.X.Li R.Li S.X.Li T.Li W.D.Li W.G.Li X.Li X.H.Li X.L.Li X.Z.Li Xi Institute of High Energy Physics Beijing 100049China Beihang University Beijing 100191China bochum Ruhr-University D-44780BochumGermany Budker Institute of Nuclear Physics SB RAS(BINP) Novosibirsk 630090Russia Carnegie Mellon University PittsburghPennsylvania 15213USA Central China Normal University Wuhan 430079China Central South University Changsha 410083China China Center of Advanced Science and Technology Beijing 100190China China University of Geosciences Wuhan 430074China Chung-Ang University Seoul06974Republic of Korea COMSATS University Islamabad Lahore CampusDefence RoadOff Raiwind Road54000LahorePakistan Fudan University Shanghai 200433China GSI Helmholtzcentre for Heavy Ion Research GmbH D-64291DarmstadtGermany Guangxi Normal University Guilin 541004China Guangxi University Nanning 530004China Hangzhou Normal University Hangzhou 310036China Hebei University Baoding 071002China Helmholtz Institute Mainz Staudinger Weg 18D-55099MainzGermany Henan Normal University Xinxiang 453007China Henan University Kaifeng 475004China Henan University of Science and Technology Luoyang 471003China Henan University of Technology Zhengzhou 450001China Huangshan College Huangshan 245000China Hunan Normal University Changsha 410081China Hunan University Changsha 410082China Indian Institute of Technology Madras Chennai 600036India Indiana University BloomingtonIndiana 47405USA INFN Laboratori Nazionali di Frascati (A)INFN Laboratori Nazionali di FrascatiI-00044FrascatiItaly(B)INFN Sezione di PerugiaI-06100PerugiaItaly(C)University of PerugiaI-06100PerugiaItaly INFN Sezione di Ferrara (A)INFN Sezione di FerraraI-44122FerraraItaly(B)University of FerraraI-44122FerraraItaly Inner Mongolia University Hohhot 010021China Institute of Modern Physics Lanzhou 730000China Institute of Physics and Technology Peace Avenue 54BUlaanbaatar 13330Mongolia Instituto de Alta Investigación Universidad de TarapacáCasilla 7DArica 1000000Chile Jilin University Changchun 130012China Joha

The number ofψ(3686)events collected by the BESⅢdetector during the 2021 run period is determined to be(2259.3±11.1)×10~6 by counting inclusiveψ(3686)hadronic *** uncertainty is systematic and the statistical uncertainty is ***,the numbers ofψ(3686)events collected during the 2009 and 2012run periods are updated to be(107.7±0.6)×10~6 and(345.4±2.6)×10~6,*** numbers are consistent with the previous measurements within one standard *** total number ofψ(3686)events in the three data samples is(2712.4±14.3)×10~6.

关键词： ψ(3686) inclusive process Hadronic events BESⅢdetector

Comparison of long-term clinical outcome after successful implantation of Firebird sirolimus-and Taxus paclitaxel-eluting stents in Chinese population： analysis of a large single center registry

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2010年第7期123卷 810-815页

作者： DOU ke-fei XU bo YANG yue-jin CHEN Ji-lin QIAO Shu-bin wang Yang LI Jian-jun qin Xue-wen YAO Min liu Hai-bo WU Yong-jian CHEN Jue YUAN Jin-qing YOU Shi-jie LI Wei GAO Run-lin Department of Cardiology Cardiovascular Institute and Fu Wai Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing 100037 China

Background Recent studies have shown that drug eluting stent （DES） implantation improved clinical outcome concerning efficacy compared with bare-metal stent （BMS） implantation, and sirolimus-eluting stent （SES） seemed superior to paclitaxel-eluting stent （PES） in improving the outcomes. Firebird SES is the most widely used SES in China. Long-term comparison of safety and efficacy between Firebird SES and Taxus PES in Chinese popuation is still not available. The aim of this research was to compare the safety and efficacy at 24 months after the successful implantation of Firebird SES and TAXUS PES in Chinese *** From April 2004 to October 2006, 3110 consecutive patients who underwent successful DES （Firebird SES 2274; Taxus PES 836） implantation were prospectively enrolled into this study. All enrolled patients were divided into two groups based on stent type. By outpatient clinic visit and telephone interview, we obtained 24-month clinical outcome including death, myocardial infarction （Ml）, thrombosis, target lesion revascularization （TLR）, target vessel revascularization （TVR）, and major adverse cardiac events （MACE, the composite of death, Ml, and TVR）. We used Cox＇s proportional-hazards models to assess relative risks of all the outcome measures before and after propensity match. Results Unadjusted clinical outcomes indicated that the patients treated with Firebird SES were associated with lower risk of TLR （HR0.38, 95%CI 0.26-0.54）, TVR （HR 0.51,95%CI 0.38-0.68） and MACE （HR 0.53, 95%CI 0.41-0.68）. The results after propensity match were consistent with that before matching, lower risk of TLR （HR 0.33, 95%CI 0.19-0.58）, TVR （HR 0.41, 95%CI 0.26-0.64）, MACE （HR 0.48, 95%CI 0.33-0.68） in Firebird *** Compared with Taxus PES, the use of domestic Firebird SES may decrease the risk of TLR, TVR and MACE in daily practice.

关键词： treatment outcome Firebird sirolimus-eluting stent Taxus paclitaxel-eluting stent

3-to 24-month Follow-up on COVID-19 with Pulmonary Tuberculosis Survivors after Discharge:Results from a Prospective,Multicenter Study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Biomedical and Environmental Sciences 2022年第12期35卷 1091-1099页

作者： wang Jing Ya ZONG Xing Yu WU Gui Hui QI Yuan Lin LI Hui Zhen JI Xin Yu TONG Lin ZHANG Lei YANG Ming bo YANG Pu Ye LI Ji ke XIAO Fu Rong ZHANG Lin Song HU Yun hong liu hong De XU Shou Fang SUN Sheng WU Wei MAO Ya LI Min qing HOU Hao Hua GONG Zhao Yuan GUO Yang JIAO Li Wen qin Jin wang Ding Yi wang Fang GUAN Li LIN Gang MA Yan wang Yan ping SHI Nan Nan Community Health Service Management Center Dongcheng DistrictBeijing 100700China Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical SciencesBeijing 100700China Public Health Clinical Center of Chengdu Chengdu 610066SichuanChina Yiyuan TCM Hospital Zibo 256199ShandongChina Institute of Information on Traditional Chinese Medicine China Academy of Chinese Medical SciencesBeijing 100700China Xi’an Eighth Hospital Xi’an 710000ShaanxiChina Harbin Infectious Disease Hospital Harbin 150000HeilongjiangChina Hospital(T.C.M)Affiliated to Southwest Medical University Luzhou 646000SichuanChina Xingtai Hospital of Chinese Medicine Xingtai 054000HebeiChina Shijiazhuang Fifth Hospital Shijiazhuang 050000HebeiChina Jiamusi Infectious Disease Hospital Jiamusi 154000HeilongjiangChina Chengde Hospital of Traditional Chinese Medicine Chengde 067040HebeiChina Hanzhong Central Hospital Hanzhong 723000ShaanxiChina Ankang Hospital of Traditional Chinese Medicine Ankang 725000ShaanxiChina Department of Traditional Chinese medicine Dazhou Central HospitalDazhou 635000SichuanChina China National Medicines Corporation Ltd Beijing 100077China Beijing University of Chinese Medicine Beijing 101121China Infectious Disease Hospital of Heilongjiang Province Harbin 150030HeilongjiangChin

Objective Coronavirus disease 2019(COVID-19)and tuberculosis(TB)are major public health and social issues *** long-term follow-up of COVID-19 with pulmonary TB(PTB)survivors after discharge is *** study aimed to comprehensively describe clinical outcomes,including sequela and recurrence at 3,12,and 24 months after discharge,among COVID-19 with PTB *** From January 22,2020 to May 6,2022,with a follow-up by August 26,2022,a prospective,multicenter follow-up study was conducted on COVID-19 with PTB survivors after discharge in 13 hospitals from four provinces in *** outcomes,including sequela,recurrence of COVID-19,and PTB survivors,were collected via telephone and face-to-face interviews at 3,12,and 24 months after *** Thirty-two COVID-19 with PTB survivors were *** median age was 52(45,59)years,and 23(71.9%)were *** them,nearly two-thirds(62.5%)of the survivors were moderate,three(9.4%)were severe,and more than half(59.4%)had at least one comorbidity(PTB excluded).The proportion of COVID-19 survivors with at least one sequela symptom decreased from 40.6%at 3 months to 15.8%at 24 months,with anxiety having a higher proportion over a *** and amnesia recovered at the 12-month follow-up,while anxiety,fatigue,and trouble sleeping remained after ***,one(3.1%)case presented two recurrences of PTB and no re-positive COVID-19during the follow-up *** The proportion of long symptoms in COVID-19 with PTB survivors decreased over time,while nearly one in six still experience persistent symptoms with a higher proportion of *** recurrence of PTB and the psychological support of COVID-19 with PTB after discharge require more attention.

关键词： COVID-19 Pulmonary tuberculosis Long-term Sequela Recurrence Re-positive

Comparison of long-term clinical outcome after successful implantation of FIREBIRD and CYPHER sirolimus-eluting stents in daily clinical practice： analysis of a large single-center registry

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2011年第7期124卷 990-996页

作者： XU bo DOU ke-fei YANG yue-jin CHEN Ji-lin QIAO Shu-bin wang Yang LI Jian-jun qin Xue-wen YAO Min liu Hai-bo WU Yong-jian CHEN Jue YUAN Jin-qing YOU Shi-jie LI Wei GAO Run-lin Cardiac Catheterization Lab (Xu B) Cardiovascular Institute and Fu Wai Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing 100037 China Department of Cardiology Cardiovascular Institute and Fu Wai Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing 100037 China

Background Recent data have shown that sirolimus-eluting stents （SES） reduced not only the incidences of restenosis but also of target vessel revascularization （TVR）. CYPHER and FIREBIRD stents are both widely used SES in China. However, comparative data concerning differences in long-term safety and efficacy regarding CYPHER and FIREBIRD stents in the Chinese population are still not available.

关键词： clinical outcome sirolimus-eluting stent CYPHER stent FIREBIRD stent

搅拌摩擦焊焊缝缺陷形态对超声相控阵检测的影响

在线全文

学校读者我要写书评

暂无评论

中国有色金属学报 2019年第3期29卷 491-497页

作者：胡博文黄春平夏春刘钺柯黎明南昌航空大学轻合金加工科学与技术国防重点学科实验室南昌330063 江西省锅炉压力容器检验检测研究院南昌330063

搅拌摩擦焊缺陷界面紧贴、细微、取向复杂,常用的检测方法在角度选择及缺陷判别上存在难点,超声相控阵可在单一探头上实现多角度聚焦扫查。以不同形态未焊透(LOP)和隧道孔作为研究对象,采用超声相控阵扇扫,研究了界面取向和曲率对检测... 详细信息

搅拌摩擦焊缺陷界面紧贴、细微、取向复杂,常用的检测方法在角度选择及缺陷判别上存在难点,超声相控阵可在单一探头上实现多角度聚焦扫查。以不同形态未焊透(LOP)和隧道孔作为研究对象,采用超声相控阵扇扫,研究了界面取向和曲率对检测的影响。结果表明:超声相控阵扇扫可不移动探头对未焊透和隧道孔进行精确识别;平直未焊透界面检测受界面取向及入射角的共同影响,信号强度与声束和界面偏离垂直的程度呈反比,弯曲未焊透界面检测受界面曲率影响,信号强度与曲率成反比,综合多角度检测得到的角度-幅值曲线可以判断未焊透界面是否弯曲。

关键词：搅拌摩擦焊超声相控阵扇扫未焊透隧道孔界面形态

Two-year clinical outcomes following elective drug-eluting versus bare-metal stent implantation： results from a large single-center database

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2009年第19期122卷 2261-2267页

作者： GAO Run-lin XU bo CHEN Ji-lin YANG yue-jin QIAO Shu-bin wang Yang DOU ke-fei qin Xue-wen YAO Min liu Hai-bo WU Yong-jian YUAN Jin-qing CHEN Jue YOU Shi-jie DAI Jun MA Wei-hua LI Wei Department of Cardiology Cardiovascular Institute & Fu Wai Hospital Chinese Academy of Medical Sciences Peking Union Medical College Beijing 100037 China Catheterization Laboratory Cardiovascular Institute & Fu Wai Hospital Chinese Academy of Medical Sciences Peking Union Medical College Beijing 100037 China Division of Biometrics Cardiovascular Institute & Fu Wai Hospital Chinese Academy of Medical Sciences Peking Union Medical College Beijing 100037 China

Background In response to the increasing concern with the safety of the drug-eluting stent （DES）, the present study aimed to evaluate the long-term safety and efficacy of DES used for a Chinese patient population. Methods All patients, who underwent an index elective percutaneous coronary intervention with an implantation of either DES or bare-metal stent （BMS） in a single institution from April 2004 to December 2006, were included in the analysis. A propensity-score matching technique was applied to adjust and to minimize the impact of confounding factors. Results Overall, there were 1465 patients （20.2%） who had undergone an implantation of only BMS, and 5769 patients （79.8%） of only DES. The propensity-score matching technique set up 1321 pairs of patients for analysis. There were no significant differences between the rates of stent thrombosis （definite and probable） of the two groups （1.06% vs 1.21%, P=0.8580）. Although rates of mortality and myocardial infarction （MI） during the 2-year follow-up period had not differed significantly, rates of death/MI （3.0% vs 4.5%, P=0.0263）, target-lesion revascularization （TLR, 3.2% vs 8.5, P=0.0001）, target-vessel revascularization （TVR, 5.8% vs 9.5%, P 〈0.0001） and any revascularization （10.0% vs 13.3%, P=0.0066） were significantly lower for the DES group than for the BMS group. Among the patients in whom devices were implanted for off-label indications, the propensity-score matched rates of stent thrombosis, mortality, MI, and death/MI were not significantly different, while rates of TLR, TVR and any revascularization were significantly lower for the DES group than for the BMS group. Conclusions During the 2 years of follow-up post stenting, DES use is associated with lower rates of death/MI, TLR, TVR and any revascularization, compared with BMS, in propensity-score matched Chinese patient populations. In the setting of off-label usage, DES use is also associated with similar advantages.

关键词： stent drug eluting bare metal registry propensity score